{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.2","upperLimit":"78.5","value":"67.6"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.7","upperLimit":"32.1","value":"20.6"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.3","upperLimit":"18.2","value":"8.8"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"10.2","value":"2.9"}]}],"title":"Progressive disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"BOR consists of (Complete response \\[CR\\], Partial response \\[PR\\], stable disease \\[SD\\], progressive disease \\[PD\\] and unknown). CR: disappearance of all detectable clinical evidence; PR: 50% decrease in the sum of the product of diameters (SPD) of up to 6 largest dominant nodal masses and \\>= 50% decrease in SPD of spleen/liver nodules; PD: appearance of any new lesions or \\>= 50% increase in SPD of more than one node or \\>= 50% increase in longest diameter of a previously identified node or \\>50% increase from nadir in the SPD of any previous lesions; SD: failure to attain CR/PR or PD. Percentages were rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"NUMBER","populationDescription":"Participants from the mITT Analysis Set in Cohort 1 were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 7.8 years","title":"Percentage of Participants With Best Objective Response (BOR) as Per Investigator Assessment Determined by International Working Group (IWG) 2007 Criteria in Cohort 1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}